all report title image

NEUROPLASTICITY MARKET ANALYSIS

Neuroplasticity Market, By Product Type (Software-Based Solutions, Hardware-Based Solutions), By Application (Stroke Rehabilitation, Traumatic Brain Injury (TBI) Rehabilitation, Neurodegenerative Disorders, Learning and Memory Enhancement, Mental Health Disorders), By End User (Hospitals and Clinics, Research Institutes and Academic Centers, Pharmaceutical and Biotechnology Companies, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Feb 2024
  • Code : CMI6032
  • Pages :150
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Regional Analysis

Neuroplasticity Market Regional Insights

  • North America is expected to dominate the global neuroplasticity market with a market share of over 33.0% in 2023. For instance, according to data published in December 2022 by the Parkinson's Foundation, an estimated 930,000 people in the U.S. were suffering from Parkinson's disease in 2020.
  • Europe is the second-largest market for neuroplasticity, with a market share of over 20.0% in 2023. This is due to the increasing awareness about brain health and neuroplasticity in the region, which is supporting the development and adoption of neuroplasticity therapies. For instance, in February 2021, the World Federation of Neurology, an organization based in Brussels, Belgium, which aims to foster quality neurology and brain health worldwide, announced the launch of the Brain Health Initiative, a global campaign to promote the importance of brain health. This initiative centers on free, comprehensive information on a variety of topics such as why brain health is important and what happens when brains are not healthy. The program aims to reduce the burden of brain diseases and disorders, which are the second leading cause of death globally.
  • Asia Pacific is the third largest market for neuroplasticity, with a market share of over 18.0% in 2023. This is due to an increase in the research and development activities in the region. For instance, in November 2020, the National Institute of Mental Health and Neuro Sciences, India, initiated a clinical trial titled “Examining Neuroplasticity Modulation as the Mechanistic Basis of tDCS Treatment Effects on Auditory Verbal Hallucination in Schizophrenia”. The study is estimated to be completed on August 31, 2025.

Figure 1. Global Neuroplasticity Market Share (%), By Region, 2023

request-sample
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East & Africa:  GCC Countries, Israel,  South Africa, North Africa, and Central Africa and Rest of Middle East

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.